Theratechnologies Starts Commercialization of New EGRIFTA SV?? in the United States
Theratechnologies Inc. - Common Shares (THTX)
Company Research
Source: GlobeNewswire
MONTREAL, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SV?? (2mg/vial) is now commercially available in the United States. Our salesforce has started detailing the product to physicians today while the supply chain is being filled, and people living with HIV and lipodystrophy will have access to a new formulation of tesamorelin for the reduction of hard belly (excess hard abdominal fat) in the next few days. Lipodystrophy is a serious metabolic condition which is associated with the development of insulin resistance, diabetes, fatty liver and high triglyceride levels. EGRIFTA SV?? is a growth hormone-releasing factor analog. EGRIFTA SV?? is a once-daily small volume subcutaneous injection that is presented in a single vial and stored at room temperature. “Given its many improvements over the original version of tesamorelin, EGRIFTA SV?? shoul
Show less
Read more
Impact Snapshot
Event Time:
THTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THTX alerts
High impacting Theratechnologies Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
THTX
News
- Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment [Canadian Business Journal (Canada)]Canadian Business Journal
- Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing EnvironmentGlobeNewswire
- Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA [Canadian Business Journal (Canada)]Canadian Business Journal
- Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLAGlobeNewswire
- Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
THTX
Sec Filings
- 12/19/24 - Form 6-K
- 12/12/24 - Form 6-K
- 12/11/24 - Form 6-K
- THTX's page on the SEC website